129 related articles for article (PubMed ID: 23690220)
1. Differences in the expression of telomerase and prostate-specific membrane antigen in non-advanced prostatic cancer.
Gasinska A; Luczynska E; Wilk W; Cichocka A
Folia Histochem Cytobiol; 2013; 51(1):66-72. PubMed ID: 23690220
[TBL] [Abstract][Full Text] [Related]
2. Expression of Ki-67 (MIB-1) and GLUT-1 proteins in non-advanced prostatic cancer.
Luczynska E; Gasinska A; Wilk W
Pol J Pathol; 2012 Dec; 63(4):272-7. PubMed ID: 23359198
[TBL] [Abstract][Full Text] [Related]
3. More advantages in detecting bone and soft tissue metastases from prostate cancer using
Pianou NK; Stavrou PZ; Vlontzou E; Rondogianni P; Exarhos DN; Datseris IE
Hell J Nucl Med; 2019; 22(1):6-9. PubMed ID: 30843003
[TBL] [Abstract][Full Text] [Related]
4. Microvessel density and expression of vascular endothelial growth factor in clinically localized prostate cancer.
Łuczyńska E; Gasińska A; Wilk W
Pol J Pathol; 2013 Apr; 64(1):33-8. PubMed ID: 23625598
[TBL] [Abstract][Full Text] [Related]
5.
Maurer T; Robu S; Schottelius M; Schwamborn K; Rauscher I; van den Berg NS; van Leeuwen FWB; Haller B; Horn T; Heck MM; Gschwend JE; Schwaiger M; Wester HJ; Eiber M
Eur Urol; 2019 Apr; 75(4):659-666. PubMed ID: 29625755
[TBL] [Abstract][Full Text] [Related]
6. Expression of prostate specific membrane antigen (PSMA) in prostatic adenocarcinoma and prostatic intraepithelial neoplasia.
Marchal C; Redondo M; Padilla M; Caballero J; Rodrigo I; García J; Quian J; Boswick DG
Histol Histopathol; 2004 Jul; 19(3):715-8. PubMed ID: 15168332
[TBL] [Abstract][Full Text] [Related]
7. Prognostic Significance of Serum PSA Level and Telomerase, VEGF and GLUT-1 Protein Expression for the Biochemical Recurrence in Prostate Cancer Patients after Radical Prostatectomy.
Gasinska A; Jaszczynski J; Rychlik U; Łuczynska E; Pogodzinski M; Palaczynski M
Pathol Oncol Res; 2020 Apr; 26(2):1049-1056. PubMed ID: 30989489
[TBL] [Abstract][Full Text] [Related]
8. Telomerase reverse transcriptase subunit immunoreactivity: a marker for high-grade prostate carcinoma.
Iczkowski KA; Pantazis CG; McGregor DH; Wu Y; Tawfik OW
Cancer; 2002 Dec; 95(12):2487-93. PubMed ID: 12467061
[TBL] [Abstract][Full Text] [Related]
9. [Correlation study of expression levels of prostate-specific membrane antigen and prostate-specific antigen with Gleason score of prostate carcinoma].
Ren JQ; Chen ZQ; Zheng L; Chen Q; Li H; Zhu HG
Zhonghua Zhong Liu Za Zhi; 2004 Dec; 26(12):735-8. PubMed ID: 15733392
[TBL] [Abstract][Full Text] [Related]
10. Comparison of serum prostate specific membrane antigen, prostate specific antigen, and free prostate specific antigen levels in radical prostatectomy patients.
Douglas TH; Morgan TO; McLeod DG; Moul JW; Murphy GP; Barren R; Sesterhenn IA; Mostofi FK
Cancer; 1997 Jul; 80(1):107-14. PubMed ID: 9210715
[TBL] [Abstract][Full Text] [Related]
11. The role of (
Yilmaz U; Komek H; Can C; Altindag S
Ann Nucl Med; 2019 Aug; 33(8):545-553. PubMed ID: 31069696
[TBL] [Abstract][Full Text] [Related]
12. Cellular distribution and heterogeneity of Psa and Psma expression in normal, hyperplasia and human prostate cancer.
Ben Jemaa A; Bouraoui Y; Sallami S; Banasr A; Nouira Y; Horchani A; Oueslati R
Tunis Med; 2013 Jul; 91(7):458-63. PubMed ID: 24008878
[TBL] [Abstract][Full Text] [Related]
13. Androgen ablation therapy for prostate carcinoma suppresses the immunoreactive telomerase subunit hTERT.
Iczkowski KA; Huang W; Mazzucchelli R; Pantazis CG; Stevens GR; Montironi R
Cancer; 2004 Jan; 100(2):294-9. PubMed ID: 14716763
[TBL] [Abstract][Full Text] [Related]
14.
Uprimny C; Kroiss AS; Decristoforo C; Fritz J; von Guggenberg E; Kendler D; Scarpa L; di Santo G; Roig LG; Maffey-Steffan J; Horninger W; Virgolini IJ
Eur J Nucl Med Mol Imaging; 2017 Jun; 44(6):941-949. PubMed ID: 28138747
[TBL] [Abstract][Full Text] [Related]
15. Molecular staging of pelvic surgical margins after radical prostatectomy: comparison of RT-PCR for prostate-specific antigen and telomerase activity.
Straub B; Müller M; Krause H; Goessl C; Schrader M; Heicappell R; Miller K
Oncol Rep; 2002; 9(3):545-9. PubMed ID: 11956625
[TBL] [Abstract][Full Text] [Related]
16. Immunohistochemical localization of human kallikreins 6, 10 and 13 in benign and malignant prostatic tissues.
Petraki CD; Gregorakis AK; Papanastasiou PA; Karavana VN; Luo LY; Diamandis EP
Prostate Cancer Prostatic Dis; 2003; 6(3):223-7. PubMed ID: 12970725
[TBL] [Abstract][Full Text] [Related]
17. The utility of PSMA and PSA immunohistochemistry in the cytologic diagnosis of metastatic prostate carcinoma.
Bernacki KD; Fields KL; Roh MH
Diagn Cytopathol; 2014 Jul; 42(7):570-5. PubMed ID: 24273068
[TBL] [Abstract][Full Text] [Related]
18. Short term neoadjuvant androgen deprivation therapy does not affect prostate specific membrane antigen expression in prostate tissues.
Chang SS; Reuter VE; Heston WD; Hutchinson B; Grauer LS; Gaudin PB
Cancer; 2000 Jan; 88(2):407-15. PubMed ID: 10640975
[TBL] [Abstract][Full Text] [Related]
19. Association of very low prostate-specific antigen levels with increased cancer-specific death in men with high-grade prostate cancer.
Mahal BA; Aizer AA; Efstathiou JA; Nguyen PL
Cancer; 2016 Jan; 122(1):78-83. PubMed ID: 26371600
[TBL] [Abstract][Full Text] [Related]
20. Dissociation between androgen responsiveness for malignant growth vs. expression of prostate specific differentiation markers PSA, hK2, and PSMA in human prostate cancer models.
Denmeade SR; Sokoll LJ; Dalrymple S; Rosen DM; Gady AM; Bruzek D; Ricklis RM; Isaacs JT
Prostate; 2003 Mar; 54(4):249-57. PubMed ID: 12539223
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
